Emerging biotech companies operate at the intersection of breakthrough science and growing operational complexity, often with lean teams and high stakes. Success in oncology development requires strong science and practical planning, risk-aware decision-making, and the ability to balance speed with sound judgment. In this video, Panteli Theocharous, PhD, FRCPath, Chief Therapeutics & Clinical Strategy Officer and President of Europe, shares guidance for biotech leaders on pressure-testing study assumptions before launch, scaling programs without losing agility, and keeping the patient perspective central throughout development.
In this brief video, you’ll learn:
- How to pressure-test a study before launch, including protocol feasibility, site strategy, biomarker criteria, enrollment assumptions, and why restrictive eligibility can shrink an already small patient pool.
- What it takes to scale without losing agility, such as building coordination, visibility, and governance as programs grow, and when external support can add capacity without building every capability internally.
- Practical guidance for biotech leaders, focusing on today’s priorities, planning for risks, and pairing operational preparation with scientific strategy to keep patients central.
Authors:
Panteli Theocharous, PhD, FRCPath
Chief Therapeutics & Clinical Strategy Officer and President of Europe
